Taken together, these results show that two different rP18tri-based TB vaccines (TBvac-2 and TBvac-10) administered systemically, mucosally, or a combination of the two, elicit strong antigen-specific CD8 T cells in the spleen, peripheral blood, and lungs. This evidence concerns the gene CD8A and tuberculosis.